31.92
+0.62(+1.98%)
Currency In USD
| Previous Close | 31.3 |
| Open | 30.63 |
| Day High | 31.96 |
| Day Low | 29.78 |
| 52-Week High | 103.81 |
| 52-Week Low | 29.78 |
| Volume | 2.92M |
| Average Volume | 1.2M |
| Market Cap | 1.78B |
| PE | -20.86 |
| EPS | -1.53 |
| Moving Average 50 Days | 36.02 |
| Moving Average 200 Days | 51.82 |
| Change | 0.62 |
If you invested $1000 in PROCEPT BioRobotics Corporation (PRCT) since IPO date, it would be worth $761.09 as of November 09, 2025 at a share price of $31.92. Whereas If you bought $1000 worth of PROCEPT BioRobotics Corporation (PRCT) shares 3 years ago, it would be worth $810.15 as of November 09, 2025 at a share price of $31.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025
GlobeNewswire Inc.
Oct 15, 2025 8:03 PM GMT
SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
GlobeNewswire Inc.
Jul 24, 2025 10:00 PM GMT
Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif., July 24, 2025
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
GlobeNewswire Inc.
Jul 23, 2025 12:00 PM GMT
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that thre